Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 268 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer... June 27, 2020 Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Scientists uncover how incurable skin cancer resists treatment at the end... March 29, 2023 Women in Science: Celebrating with our Women of Influence initiative March 15, 2023 Load more HOT NEWS Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... This Harmful Chemical Is Still Being Used In Popular Household Products When Cancer Isn’t Your Only Challenge: How I Learned to Cope New tool to tackle gaps in public’s knowledge of blood cancer...
